Cell Biotech Co

Cell Biotech Co Net Tangible Assets

The Net Tangible Assets of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 131.64 B KRW. In the previous year, Net Tangible Assets was 122.56 B KRW — a change of 7.40% (higher).

Net Tangible Assets

131.64 BKRW

YoY

7.40%

Last updated:

Net Tangible Assets of Cell Biotech Co is 2025 131.64 B KRW. Net Tangible Assets of Cell Biotech Co was 2024 122.56 B KRW. It decreases by 7.40% higher compared to the previous year.

The Cell Biotech Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
104.52 B KRW
Jan 1, 2019
101.90 B KRW
Jan 1, 2020
98.18 B KRW
Jan 1, 2021
105.15 B KRW
Jan 1, 2022
106.30 B KRW
Jan 1, 2023
110.29 B KRW
Jan 1, 2024
122.56 B KRW
Jan 1, 2025
131.64 B KRW
The Cell Biotech Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
131.64 BKRW+7.40%
122.56 BKRW+11.13%
110.29 BKRW+3.75%
106.30 BKRW+1.09%
105.15 BKRW+7.10%
98.18 BKRW-3.65%
101.90 BKRW-2.50%
104.52 BKRW+17.31%
89.10 BKRW+7.07%
83.21 BKRW+22.53%
67.91 BKRW+31.41%
51.68 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Net Tangible Assets of Cell Biotech Co is 131.64 B KRW in 2025.

Net Tangible Assets of Cell Biotech Co changed from 122.56 B KRW to 131.64 B KRW, representing a 7.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cell Biotech Co

All Key Metrics — Cell Biotech Co